Overview Dividends

(AMRZ) Amrize - Ratings and Ratios

Exchange: NYSE • Country: Switzerland • Currency: USD • Type: Common Stock • ISIN: (N/A)

Cement, Aggregates, Ready-Mix Concrete, Building Materials

Construction Materials
Market Cap in USD: 27,460m

IPO / Inception: 2025-06-23
Return 12m vs S&P 500: -5.21%

EPS (Earnings per Share)

EPS CAGR: 20545.15%
EPS Trend: 91.3%

Qual. Beats: 0

Revenue

Rev. CAGR: 14.18%
Rev. Trend: 28.7%

Qual. Beats: 0

Dividends

Currently no dividends paid

Risk via 5d forecast
Volatility	30.0%
Value at Risk 5%th	46.6%
Relative Tail Risk	-5.47%

Reward TTM
Sharpe Ratio	0.60
Alpha	-9.84
CAGR/Max DD	1.24

Character TTM
Hurst Exponent	0.513
Beta	1.052
Beta Downside	0.402

Drawdowns 3y
Max DD	15.59%
Mean DD	6.47%
Median DD	5.26%

Description: AMRZ Amrize November 14, 2025

Amrize Ltd (NYSE: AMRZ) is a newly-incorporated Swiss holding that focuses on the North-American building-materials market. Established in 2023 and headquartered in Zug, the firm formally separated from its former parent Holcim AG on 23 June 2025, operating as an independent public company listed on the NYSE.

Key industry metrics that will likely drive Amrize’s performance include: (1) U.S. residential construction starts, which have risen ~4 % YoY in Q2 2025, supporting demand for cement and aggregates; (2) the average selling price (ASP) for ready-mix concrete, which has climbed roughly 2 % year-over-year amid tightening supply chains; and (3) ESG-related capital expenditures, with peers allocating ~5 % of capex to low-carbon cement technologies, a trend that could affect Amrize’s cost structure and investor appeal. These drivers are publicly reported in the building-materials sector and provide a baseline for assessing Amrize’s growth prospects.

For a deeper, data-driven view of Amrize’s valuation and risk profile, you may want to explore the analyst tools on ValueRay, which aggregate real-time financial metrics and sector benchmarks.

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income (1.38b TTM) > 0 and > 6% of Revenue (6% = 709.5m TTM)

FCFTA 0.06 (>2.0%) and ΔFCFTA 0.13pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 11.98% (prev 24.41%; Δ -12.43pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.09 (>3.0%) and CFO 2.13b > Net Income 1.38b (YES >=105%, WARN >=100%)

Net Debt (6.06b) to EBITDA (2.80b) ratio: 2.17 <= 3.0 (WARN <= 3.5)

Current Ratio 1.45 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (553.9m) change vs 12m ago 0.16% (target <= -2.0% for YES)

Gross Margin 25.80% (prev 25.09%; Δ 0.71pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 49.23% (prev 49.03%; Δ 0.20pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 4.83 (EBITDA TTM 2.80b / Interest Expense TTM 394.0m) >= 6 (WARN >= 3)

Altman Z'' 1.02

(A) 0.06 = (Total Current Assets 4.57b - Total Current Liabilities 3.15b) / Total Assets 24.04b

(B) 0.03 = Retained Earnings (Balance) 601.0m / Total Assets 24.04b

(D) 0.01 = Book Value of Equity 167.0m / Total Liabilities 11.14b

Total Rating: 1.02 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 66.42

1. Piotroski 6.50pt

2. FCF Yield 4.22%

3. FCF Margin 11.97%

4. Debt/Equity 0.53

5. Debt/Ebitda 2.17

6. ROIC - WACC (= 0.13)%

7. RoE 10.79%

8. Rev. Trend 28.69%

9. EPS Trend 91.28%

What is the price of AMRZ shares?

As of January 10, 2026, the stock is trading at USD 57.32 with a total of 3,168,121 shares traded.
Over the past week, the price has changed by +3.41%, over one month by +7.12%, over three months by +19.12% and over the past year by +10.25%.

Is AMRZ a buy, sell or hold?

Amrize has no consensus analysts rating.

What are the forecasts/targets for the AMRZ price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	57.9	1.1%
Analysts Target Price	-	-
ValueRay Target Price	58	1.1%

AMRZ Fundamental Data Overview January 10, 2026

P/E Trailing = 19.4824
P/E Forward = 18.1818
P/S = 2.3634
P/B = 2.1989
P/EG = 1.5882
Beta = None
Revenue TTM = 11.82b USD
EBIT TTM = 1.90b USD
EBITDA TTM = 2.80b USD
Long Term Debt = 4.93b USD (from longTermDebt, last quarter)
Short Term Debt = 1.11b USD (from shortTermDebt, last quarter)
Debt = 6.89b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.06b USD (from netDebt column, last quarter)
Enterprise Value = 33.52b USD (27.46b + Debt 6.89b - CCE 826.0m)
Interest Coverage Ratio = 4.83 (Ebit TTM 1.90b / Interest Expense TTM 394.0m)
EV/FCF = 23.67x (Enterprise Value 33.52b / FCF TTM 1.42b)
FCF Yield = 4.22% (FCF TTM 1.42b / Enterprise Value 33.52b)
FCF Margin = 11.97% (FCF TTM 1.42b / Revenue TTM 11.82b)
Net Margin = 11.65% (Net Income TTM 1.38b / Revenue TTM 11.82b)
Gross Margin = 25.80% ((Revenue TTM 11.82b - Cost of Revenue TTM 8.77b) / Revenue TTM)
Gross Margin QoQ = 29.55% (prev 30.0%)
Tobins Q-Ratio = 1.39 (Enterprise Value 33.52b / Total Assets 24.04b)
Interest Expense / Debt = 1.29% (Interest Expense 89.0m / Debt 6.89b)
Taxrate = 21.65% (150.0m / 693.0m)
NOPAT = 1.49b (EBIT 1.90b * (1 - 21.65%))
Current Ratio = 1.45 (Total Current Assets 4.57b / Total Current Liabilities 3.15b)
Debt / Equity = 0.53 (Debt 6.89b / totalStockholderEquity, last quarter 12.90b)
Debt / EBITDA = 2.17 (Net Debt 6.06b / EBITDA 2.80b)
Debt / FCF = 4.28 (Net Debt 6.06b / FCF TTM 1.42b)
Total Stockholder Equity = 12.78b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.74% (Net Income 1.38b / Total Assets 24.04b)
RoE = 10.79% (Net Income TTM 1.38b / Total Stockholder Equity 12.78b)
RoCE = 10.75% (EBIT 1.90b / Capital Employed (Equity 12.78b + L.T.Debt 4.93b))
RoIC = 8.16% (NOPAT 1.49b / Invested Capital 18.28b)
WACC = 8.03% (E(27.46b)/V(34.35b) * Re(9.79%) + D(6.89b)/V(34.35b) * Rd(1.29%) * (1-Tc(0.22)))
Discount Rate = 9.79% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.11%
[DCF Debug] Terminal Value 78.34% ; FCFF base≈1.40b ; Y1≈1.44b ; Y5≈1.60b
Fair Price DCF = 39.28 (EV 27.77b - Net Debt 6.06b = Equity 21.71b / Shares 552.7m; r=8.03% [WACC]; 5y FCF grow 2.31% → 2.90% )
EPS Correlation: 91.28 | EPS CAGR: 20.5k% | SUE: N/A | # QB: 0
Revenue Correlation: 28.69 | Revenue CAGR: 14.18% | SUE: N/A | # QB: 0
EPS next Year (2026-12-31): EPS=3.00 | Chg30d=N/A | Revisions Net=+0 | Growth EPS=+14.1% | Growth Revenue=+4.4%

Additional Sources for AMRZ Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle